Results 381 to 390 of about 1,191,146 (396)

A weak signal for strong responses: interferon-alpha/beta revisited

Nature Reviews Molecular Cell Biology, 2001
Tadatsugu Taniguchi, Akinori Takaoka
exaly  

Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV

Journal of Virology, 2020
Adam Hage, Maren de Vries, Craig Schindewolf   +2 more
exaly  

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

Nature Genetics, 2009
V. Suppiah, Max Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M. Abate, M. Bassendine, U. Spengler, G. Dore, E. Powell, S. Riordan, D. Sheridan, A. Smedile, V. Fragomeli, T. Müller, M. Bahlo, G. Stewart, D. Booth, J. George   +18 more
semanticscholar   +1 more source

Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment

Cancer Cell, 2017
Angelica Ortiz, Daniel P Beiting, Ellen Puré   +2 more
exaly  

Cytokine-mediated regulation of CXCR4 expression in human neutrophils

Journal of Leukocyte Biology, 2002
Hiroyuki Nagase
exaly  

Interleukin‐18: Biological properties and role in disease pathogenesis

Immunological Reviews, 2018
Gilles Kaplanski
exaly  

Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

The Lancet, 1998
T. Poynard, P. Marcellin, Samuel S. Lee, C. Niederau, International Hepatitis Interventional Therapy Group   +4 more
semanticscholar   +1 more source

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

Journal of Infectious Diseases, 2015
Jasper Fuk-Woo Chan, Wei Deng, Linlin Bao   +2 more
exaly  

INTERFERONS

2006
J.N. Kline, K. Kitagaki
openaire   +1 more source

STING pathway agonism as a cancer therapeutic

Immunological Reviews, 2019
Jason J Luke, Thomas F Gajewski
exaly